{"entity":"vertex-pharmaceuticals","id":"ent_vertex-pharmaceuticals","name":"Vertex Pharmaceuticals","from":"2025-11-10","to":"2026-11-10","page":"https://asof.is/record/vertex-pharmaceuticals/diff?from=2025-11-10&to=2026-11-10","summary":"Between 2025-11-10 and 2026-11-10, Vertex Pharmaceuticals's record changed in 18 facts: 3 replaced (net income -$535.6 million → $3.95 billion; operating income -$232.9 million → $4.17 billion; revenue $11.02 billion → $12 billion), 8 added, 7 ended; 11 unchanged.","counts":{"changed":18,"added":8,"ended":7,"replaced":3,"unchanged":11,"skipped_posts":{"from":0,"to":0}},"by_predicate":[{"predicate":"cash_and_equivalents","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_net_income","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_operating_income","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_revenue","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"shares_outstanding","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"total_assets","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"total_equity","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"agreement","added":1,"ended":0,"replaced":0,"unchanged":1},{"predicate":"net_income","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"operating_income","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"revenue","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"cik","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"fiscal_year_end","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"headquarters","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"listed_on","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"quarterly_research_and_development","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"registrant_name","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"research_and_development","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"sic_industry","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"state_of_incorporation","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"ticker","added":0,"ended":0,"replaced":0,"unchanged":1}],"added":[{"id":"clm_14EDB54D4A3B","predicate":"agreement","value":"Crinetics Pharmaceuticals, Inc.","valid_from":"2026-07-06","valid_to":null,"published":"2026-07-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals agreement: Crinetics Pharmaceuticals, Inc.\", as of 2026-07-06. Claim clm_14EDB54D4A3B, https://asof.is/claim/clm_14EDB54D4A3B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000119312526296710/0001193125-26-296710-index.htm.","url":"https://asof.is/claim/clm_14EDB54D4A3B","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000119312526296710/0001193125-26-296710-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K","published_at":"2026-07-07T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"On July 6, 2026, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“ Parent ”), Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), and Crinetics Pharmaceuticals, Inc.","url":"https://www.sec.gov/Archives/edgar/data/875320/000119312526296710/0001193125-26-296710-index.htm"}},{"id":"clm_40B40C0D43E5","predicate":"cash_and_equivalents","value":"4,979,300,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 4,979,300,000 United States dollar\", as of 2026-09-30. Claim clm_40B40C0D43E5, https://asof.is/claim/clm_40B40C0D43E5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm.","url":"https://asof.is/claim/clm_40B40C0D43E5","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_466B90DBA1DE","predicate":"quarterly_net_income","value":"653,600,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 653,600,000 United States dollar\", as of 2026-09-30. Claim clm_466B90DBA1DE, https://asof.is/claim/clm_466B90DBA1DE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm.","url":"https://asof.is/claim/clm_466B90DBA1DE","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_60BA65E99F72","predicate":"quarterly_operating_income","value":"712,900,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 712,900,000 United States dollar\", as of 2026-09-30. Claim clm_60BA65E99F72, https://asof.is/claim/clm_60BA65E99F72, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm.","url":"https://asof.is/claim/clm_60BA65E99F72","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_30E62BBC7C14","predicate":"quarterly_revenue","value":"3,440,800,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 3,440,800,000 United States dollar\", as of 2026-09-30. Claim clm_30E62BBC7C14, https://asof.is/claim/clm_30E62BBC7C14, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm.","url":"https://asof.is/claim/clm_30E62BBC7C14","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_41CC1CCC4C8A","predicate":"shares_outstanding","value":"253,537,674 shares","valid_from":"2026-10-31","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 253,537,674 shares\", as of 2026-10-31. Claim clm_41CC1CCC4C8A, https://asof.is/claim/clm_41CC1CCC4C8A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm.","url":"https://asof.is/claim/clm_41CC1CCC4C8A","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_E8F64842EB2A","predicate":"total_assets","value":"32,736,300,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 32,736,300,000 United States dollar\", as of 2026-09-30. Claim clm_E8F64842EB2A, https://asof.is/claim/clm_E8F64842EB2A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm.","url":"https://asof.is/claim/clm_E8F64842EB2A","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_088E22D9B313","predicate":"total_equity","value":"20,907,400,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 20,907,400,000 United States dollar\", as of 2026-09-30. Claim clm_088E22D9B313, https://asof.is/claim/clm_088E22D9B313, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm.","url":"https://asof.is/claim/clm_088E22D9B313","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/0000875320-26-000291-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-11-03"}}],"ended":[{"id":"clm_2FB43E38D7CC","predicate":"cash_and_equivalents","value":"4,939,600,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals cash and equivalents: 4,939,600,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_2FB43E38D7CC, https://asof.is/claim/clm_2FB43E38D7CC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_2FB43E38D7CC","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B4475729CD2A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_2FE795B3AF8B","predicate":"quarterly_net_income","value":"1,082,900,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly net income: 1,082,900,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_2FE795B3AF8B, https://asof.is/claim/clm_2FE795B3AF8B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_2FE795B3AF8B","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_58ABF4712193","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_7EF8A5505C22","predicate":"quarterly_operating_income","value":"1,186,200,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly operating income: 1,186,200,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_7EF8A5505C22, https://asof.is/claim/clm_7EF8A5505C22, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_7EF8A5505C22","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B8F364B1BB32","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_8AB184162D82","predicate":"quarterly_revenue","value":"3,076,400,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals quarterly revenue: 3,076,400,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_8AB184162D82, https://asof.is/claim/clm_8AB184162D82, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_8AB184162D82","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_78B1FE0A2ECC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_663C199EF289","predicate":"shares_outstanding","value":"253,718,831 shares","valid_from":"2025-10-31","valid_to":"2026-02-06","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals shares outstanding: 253,718,831 shares\", as of 2025-10-31 (until 2026-02-06). Claim clm_663C199EF289, https://asof.is/claim/clm_663C199EF289, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_663C199EF289","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B7B98F7F000A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_D95598CEB876","predicate":"total_assets","value":"24,862,300,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total assets: 24,862,300,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_D95598CEB876, https://asof.is/claim/clm_D95598CEB876, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_D95598CEB876","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0090178AE4A5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-11-04"}},{"id":"clm_1E5EC8CA7B8E","predicate":"total_equity","value":"17,318,800,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals total equity: 17,318,800,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_1E5EC8CA7B8E, https://asof.is/claim/clm_1E5EC8CA7B8E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm.","url":"https://asof.is/claim/clm_1E5EC8CA7B8E","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_335F6E7CE9CE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000232/0000875320-25-000232-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-11-04"}}],"replaced":[{"predicate":"net_income","from":{"id":"clm_B3A7B0C585DF","predicate":"net_income","value":"-535,600,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals net income: -535,600,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_B3A7B0C585DF, https://asof.is/claim/clm_B3A7B0C585DF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm.","url":"https://asof.is/claim/clm_B3A7B0C585DF","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_406C31565DD9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-13"}},"to":{"id":"clm_406C31565DD9","predicate":"net_income","value":"3,953,200,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals net income: 3,953,200,000 United States dollar\", as of 2025-12-31. Claim clm_406C31565DD9, https://asof.is/claim/clm_406C31565DD9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm.","url":"https://asof.is/claim/clm_406C31565DD9","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-13"}}},{"predicate":"operating_income","from":{"id":"clm_33A4466539E6","predicate":"operating_income","value":"-232,900,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: -232,900,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_33A4466539E6, https://asof.is/claim/clm_33A4466539E6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm.","url":"https://asof.is/claim/clm_33A4466539E6","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_08B6F6FEE28A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2024, filed 2025-02-13"}},"to":{"id":"clm_08B6F6FEE28A","predicate":"operating_income","value":"4,173,300,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals operating income: 4,173,300,000 United States dollar\", as of 2025-12-31. Claim clm_08B6F6FEE28A, https://asof.is/claim/clm_08B6F6FEE28A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm.","url":"https://asof.is/claim/clm_08B6F6FEE28A","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2025, filed 2026-02-13"}}},{"predicate":"revenue","from":{"id":"clm_9011721F7C0D","predicate":"revenue","value":"11,020,100,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 11,020,100,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_9011721F7C0D, https://asof.is/claim/clm_9011721F7C0D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm.","url":"https://asof.is/claim/clm_9011721F7C0D","accessed":"2026-11-10"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B151EC07FDAE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000053/0000875320-25-000053-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2024, filed 2025-02-13"}},"to":{"id":"clm_B151EC07FDAE","predicate":"revenue","value":"12,001,300,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Vertex Pharmaceuticals revenue: 12,001,300,000 United States dollar\", as of 2025-12-31. Claim clm_B151EC07FDAE, https://asof.is/claim/clm_B151EC07FDAE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm.","url":"https://asof.is/claim/clm_B151EC07FDAE","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2025, filed 2026-02-13"}}}],"rule":"Two states compared by claim id: in both, unchanged; only on to, added; only on from, ended. An ended and an added claim on one predicate are a replacement when the ended one points to the added (superseded_by), or the predicate has exactly one of each and the added begins the day the ended ends. Added rows are labelled for to, ended rows for from. Posts and Hugging Face repos are counted in skipped_posts, not listed.","legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"page-read":"its source page states the value and the date","sec-filing":"parsed from the SEC filing"}}}